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Asthma prevalence in Italy is on the rise and is estimated to be over 6% of the general population. The diagnosis of
asthma can be challenging and elusive, especially in children and the last two decades has brought evidences that asth-
ma is not a single disease but consists of various phenotypes. Symptoms can be underestimated by the patient or under-
reported to the clinician and physical signs can be scanty. Usual objective measures, like spirometry, are necessary but
sometimes not significant. Despite proper treatment, asthma can be a very severe condition (even leading to death),
however new drugs have recently become available which can be very effective in its control. Since asthma is currently
thought to be caused by inflammation, a direct measure of the latter can be of paramount importance. For this purpose,
the measurement of Fractional Exhaled Nitric Oxide (FENO) has been used since the early years of the current century
as a non-invasive, easy-to-assess tool useful for diagnosing and managing asthma. This SIP-IRS/SIAAIC Position
Paper is a narrative review which summarizes the evidence behind the usefulness of FENO in the diagnosis, manage-
ment and phenotypization of asthma.
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Introduction and aim of the Position Paper
Asthma affects more than 300 million individuals worldwide.
It is characterized by chronic airway inflammation leading to res-
piratory symptoms (dyspnea, wheezing, chest tightness and
cough). Symptoms can vary over time and intensity and are cou-
pled with variable expiratory airflow limitation [1]. 
The prevalence of asthma in Italy is constantly increasing over
time and it is estimated to be over 6% of the general population
[2,3]. The diagnosis of asthma can be challenging. The clinical
presentation can be not very specific for the disease and it requires
the demonstration of variable airflow limitation by means of lung
function tests (i.e., spirometry, bronchodilation test, bronchial
challenges, PEF measurements) and the diagnostic process can be
even more challenging in children. Moreover, subjects with asthma
can be unaware of their sickness or anyway underestimate it, due
to infrequent symptoms or exacerbations [1]. Symptoms can be
classically triggered by exposure to allergens, respiratory tract
infections, exercise, exposure to cold air, tobacco smoke or pollu-
tion, and tend to be more frequent at night. 
Chronic airway inflammation, enhanced by the above men-
tioned triggers, contributes to induce airflow limitation that can be
assessed by lung function tests. This airflow limitation is classical-
ly reversible after administration of inhaled bronchodilators (an
increase in Forced Expiratory Volume in the first second FEV1 of
at least 200 mL and higher than 12% compared with basal value
achieved after inhalation of salbutamol 400 mcg) or after pro-
longed (i.e., after at least 4 weeks) treatment with inhaled corticos-
teroids (ICS). Airway hyperresponsiveness can be assessed by
bronchial challenge with bronchoconstrictor drugs such as metha-
choline [1]. Histamine or mannitol can also be used. Diagnosis in
children is even more challenging, since lung function tests cannot
be carried out before 5 years of age. 
Once clinical and functional diagnosis of asthma has been
established, further evaluations, including a complete allergologi-
cal workup, should be done in order to identify possible specific
triggers or predisposing conditions that may have an impact on
asthma management. In this context, Fractional Exhaled Nitric
Oxide (FENO) assessment could be taken into consideration to strat-
ify patients according to the airway inflammatory involvement [1].
Treatment of asthma is based on controller drugs with anti-
inflammatory activity [mainly ICS, but also other add-on drugs
such as leukotriene-receptor antagonists (LTRA)], possibly associ-
ated with long-acting bronchodilator drugs [generally long-acting
beta2-agonists (LABA), or long-acting muscarinic agents
(LAMA) for more severe patients] depending on the severity of the
disease [1]. The aim of the treatment is to achieve the complete
asthma control, defined as the absence of symptoms, normal lung-
function and no future risk of adverse events [1]. This should be
obtained using the least level of treatment as possible, optimizing
the adherence and the ability to correctly use inhaler’s devices as
otherwise patients could not benefit from the given therapy [4].
This emphasizes the essential role of education just after diagnosis
and in follow up [1]. If symptoms are inadequately controlled
despite treatment, adherence and the ability to use inhalers’ devices
should be revised, common comorbidities should be properly treat-
ed and any other known risk factors should be removed.
Persistence of poor asthma control and/or frequent exacerbations
and/or impaired lung function despite high dose of ICS plus anoth-
er controller and/or maintenance treatment with oral corticos-
teroids (OCS) defines “severe asthma” [5]. A referral to a severe
asthma clinic should be taken into consideration also for treatment
with novel biological agents [6]. For instance, the Severe Asthma
Network in Italy (SANI) represents a network of Italian severe
asthma centers, by the Italian Respiratory Society (SIP-IRS) and
the Italian Society of Allergy, Asthma and Immunology (SIAAIC)
[6,7]. 
Nowadays, asthma is thought to be a complex, multi-factorial
disease characterized by variable clinical presentations in different
subset of patients (the so-called “phenotypes”), resulting from het-
erogeneous expression of inflammatory pathways, involving both
innate and adaptive immune systems (the so-called “endotypes”)
[8]. Accordingly, asthma can be classified at least in two different
subgroups: one characterized by high expression of type-2
cytokines and associated inflammatory cells (“type-2 high” endo-
types), classically presenting with eosinophilic phenotypes; the
other with low expression of type-2 cytokines and characterized by
predominant neutrophilic airway inflammation [9]. A ‘mixed’
endotype has been also described coming from an overlap of these
syndromes [10].
The identification of phenotypes passes through a careful eval-
uation of any single clinical aspect, lung function patterns, sputum
and systemic inflammatory involvement. The identification of
endotypes passes through reliable and possibly non-invasive bio-
markers of inflammation.  This is crucial for establishing a preci-
sion medicine-based management [11], including the possibility to
treat patients with novel biologic agents that are showing impres-
sive results in controlling more severe asthmatics [12]. Despite the
central role of airway inflammation in the pathogenesis of asthma,
the most commonly used diagnostic algorithms, such the one pro-
posed by the Global Initiative for Asthma (GINA) [1], do not
include any assessment of airway inflammation. FENO is a non-
invasive, easy-to-assess tool to measure airway inflammation, both
in adults and children [13,14], and it could be useful for both asth-
ma diagnosis and management. This SIP-IRS/SIAAIC position
paper is a narrative review which aims to summarize the evidence
behind the usefulness of FENO in the diagnosis, management and
phenotypization of asthma.
Nitric oxide
Nitric oxide (NO) is a colorless gas that is only slightly soluble
in water (<2 mmol under standard temperature and pressure). NO
is a paramagnetic molecule with an odd number of electrons,
which implies that it is a radical with an unpaired electron that
implies an extreme reactivity responsible for many of its biological
effects [15]. The kinetics of NO autoxidation in aqueous solution
depends on its concentration [16]. Accordingly, the half-life is not
a constant value and is inversely proportional to the NO concentra-
tion, becoming much longer as nitric oxide dilution increases. At
physiological concentrations (1 μM to 10 nM), the half-life of NO
due to the reaction with oxygen (O2) is estimated to be in the 9-to-
900 min range [17]. It has been reported that when the partial oxy-
gen pressure increases in aqueous solution from 150 to 700 mmHg,
the NO half-life decreases from 6.2 to 3.8 s [18]. The short half-
life and the reactive structure of NO, in the absence of efficient free
NO storage, require a carefully controlled enzymatic NO synthetic
activity regulated through complex mechanisms of activation and
inactivation.
NO production can occur via enzymatic and non-enzymatic
pathways [19]. The enzymatic synthesis occurs from the semi-
essential amino acid L-arginine and oxygen via three isoforms of
an enzyme named nitric oxide synthase (NOS), identified in vari-
ous tissues, and it is classically classified as constitutive and
inducible. In fact, NOS-1 and NOS-3 isoforms are constitutively
expressed, while the third one (NOS-2) is generally expressed in
activated cells, although the latter may also be constitutively
expressed and be active in the paranasal sinuses [20]. NOS
enzymes have different requirements for the activation [21].
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Indeed, NOS-1 and NOS-3 are calcium-calmodulin dependent, and
are activated in response to a calcium signal. Enzyme activation
occurs rapidly and transiently. Production of NO is equally tran-
sient, providing a rapid pulse-like signal. NOS-1 and NOS-3
enzymes produce small amounts of NO. Differently from NOS-1
and -3, NOS-2 contains tightly bound calmodulin. NO synthesis
does not seem to be regulated but rather controlled at the transcrip-
tional level, and once the enzyme is expressed it will produce large
amounts of NO for prolonged periods, depending on how long the
enzyme is present in a given cell or tissue. NOS-2 expression is
dependent on transcription factors such as nuclear factor κB (NF-
κB), activated by pro-inflammatory cytokines, including tumor
necrosis factor-α (TNF-α), interleukin-1b (IL-1b) [21], interleukin
4 (IL-4) [22] and interleukin 13 (IL-13) (which upregulates NOS-
2 expression and activity) [23]. 
Apart from enzymatic synthesis pathways, endogenous pro-
duction of both NO and H2S can occur through other non-enzy-
matic processes that are less well understood. NO can be produced
in vivo by a reduction of NO3– (nitrate) to NO2– (nitrite), and NO2–
can produce NO. In fact, at low pH, nitrite will form nitrous acid
(HNO2), which decomposes to various nitrogen oxides, including
NO. Nitrite may come from either dietary intake or saliva, through
a reduction of nitrate to nitrite performed by bacteria in the oral
cavity.
Figure 1 summarized the enzymatic and non-enzymatic syn-
thesis of nitric oxide.
Biological functions of nitric oxide
The biological effects of NO in humans are numerous and
involve the whole organism, and only some of those effects are
exerted by direct actions [15]. Indeed, certain physiological and
pathophysiological effects of NO are likely to be due to derivatives
of NO rather than by this molecule itself. The direct actions of NO
occur at low concentrations by binding to a number of molecular
targets such as metal containing proteins and DNA. These interac-
tions lead to enzyme activation or inhibition. The most notable of
such processes is the reaction of NO with the heme group of
guanylyl cyclase [15]. The subsequent activation of this enzyme is
responsible for the conversion of guanosine trisphosphate (GTP)
into cyclic guanosine monophosphate (cGMP). cGMP in turn acti-
vates protein kinases that perform several regulatory functions,
including smooth muscle relaxation, neuronal transmission, and
inhibition of platelet aggregation.
On the other hand, NO can inhibit other metallo-proteins such
as cytochrome P-450, cytochrome oxidase and catalase. NO may
also modulate other oxidative reactions by interacting directly with
high energy free radicals, for example inhibiting lipid peroxidation
and reducing the generation of pro-inflammatory lipids.
In contrast to the direct actions of NO, its indirect effects are
mediated by reactive nitrogen oxide species (RNOS) derived from
the interactions of NO with O2 or O2•‒ superoxide anion [24].
Indeed, reactive nitrogen oxides have been suggested to be impor-
tant mediators of the pathophysiological events underlying a broad
spectrum of inflammatory responses. The most common reactive
nitrogen oxide species produced in vivo are dinitrogen trioxide
(N2O3) and peroxynitrite (ONOO–, an unstable structural isomer of
nitrate, NO3−), which can induce both nitrosative and oxidative
chemical stresses often associated with pathological situations
such as inflammation. An example of such phenomena can be
mediated by the potent cytotoxic and oxidant peroxynitrite and its
conjugate peroxynitrous acid ONOOH, which can oxidize thiols,
nitrate tyrosine and guanosine, as well as cleave DNA [24]. RNOS
can react with sulfhydryl containing amino acids that irreversibly
inactivate enzymes and other proteins. NO targets many enzymes
in this way, particularly those important for the mitochondrial res-
piratory chain, which is essential for ATP synthesis [24].
The role of NO in inflammation remains elusive. It is likely
that an excessive amount of NO produced by NOS-2 exerts the
same types of effects as does the “physiological” NO, including
relaxation of smooth muscle cells and vasodilatation. Thus, the
increased NO levels in inflammation may be involved in hyper-
emia, edema and hypotension. Furthermore, NO may reduce apop-
tosis of inflammatory cells such as eosinophils. On the other hand,
at high concentrations NO downregulates adhesion molecules,
suppresses activation of inflammatory cells, and induces their
apoptosis [25].
However, a different perspective on NO homeostasis in air-
way inflammation has been outlined [26]. In particular, it has been
suggested that an increased arginase activity, in conjunction with
an abnormal cellular uptake of L-arginine, may represent a major
causative factor of NOS dysfunction in asthma. L -arginine is a
substrate for both arginase and NOS, and therefore these enzymes
might affect each other activity through substrate competition. In
an allergic inflammatory microenvironment, pro-inflammatory
cytokines and “oxidative stress” might upregulate the production
of NOS-2-derived NO through activation of transcription factors
[27]. In this situation, the synthesis of strong oxidizing reactive
nitrogen species (RNS), such as peroxynitrite, leads to cell dam-
age in the airways of asthmatics. In addition, upregulation of
arginase in an inflammatory microenvironment is able to limit L-
arginine bioavailability for NOS-2, which can result in the pro-
duction of both NO and O2 as a consequence of the substrate defi-
ciency. This effect promotes an amplification of peroxynitrite for-
mation, leading to an enhanced cytotoxic action in the airways. It
might thus be speculated that a similar pathway can be activated
in the inflammatory diseases of the upper airways such as allergic
rhinitis or nasal polyposis, though this hypothesis needs to be
experimentally validated.
Figure 1. Non-enzymatic (left side) and enzymatic (right side)
synthesis of nitric oxide. NOS, Nitric Oxide Synthase. 
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Assessment of FENO
Since Gustafsson et al. [28], who reported the first detection of
NO from human expired breath, several techniques have been
developed. Nowadays, the most used are chemiluminescence,
electrochemical sensors and laser-based technology, all of which
present advantages and disadvantages in a clinical setting. FENO
could be measured both online and offline [29,30]. Online meas-
urement may provide a better data quality but offline measurement
is often more practical [31,32].
The chemiluminescence method is the gold standard for
exhaled NO analysis. NO molecules contained in the gas sample
are detected because of the radiation created after their reaction
with ozone (O3), generated in the instrument. The reaction between
NO and O3 generates nitrogen dioxide molecules (NO2 ) in an
electronically excited state. The subsequent reversion of these mol-
ecules to their lower energy ground state causes the emission of
electromagnetic radiation (photons), with wavelengths ranging
between 600-3000 nm, which can be detected and amplified by a
photomultiplier tube. The resulting output signal is determined and
corresponds linearly to the NO concentration in the sample, pro-
vided that O3 is present in excess.
The chemiluminescence equipment is highly sensitive, with a
detection threshold at ppb (parts-per-billion, 1:109) level and a very
fast response time (0.5-0.7 s). In addition, the technique allows for
direct analysis of the breath in situ, or indirectly by sampling the
breath in a balloon that can be analyzed later. However, to ensure
reliability frequent instrument calibration is often required, which
is achieved by using concentration of NO up to hundreds of ppb.
In addition, these analyzers need a source of external NO-free air
to generate ozone within the equipment, and a vacuum pump sys-
tem, which rise manufacturing costs with prices ranging between
18,000 and 41,000 EUR [33]. Furthermore, chemiluminescence
analyzers are quite large, weighing between 25 and 45 kg. All these
limitations have restricted the use of chemiluminescence analyzers
in routine clinical applications or home monitoring, and currently
remain in use solely for laboratory analysis.
Current commercially available chemiluminescence FENO ana-
lyzers include NOA 280i (Sievers, GE Analytical Instruments,
Boulder, CO, USA), NIOX (Circassia, Oxford, UK), Logan model
LR2149 (Logan Research; Rochester, Kent, UK) and CLD 88 (Eco
Medics, Duernten, Switzerland).
Electrochemical sensors can also be used to measure exhaled
NO as they convert the gas concentration into an electrical signal
[34]. The principle is based on the amperometric technique, which
is achieved in the electrochemical instrument by a buffer system
that allows retention of the last portion of the exhalation sample.
Subsequently, the sample is transferred to the sensor for analysis
where the target gas undergoes a chemical reaction in the presence
of active catalytic sensor, and a measurable physical change is
emitted within an electrical circuit. The sensor output signal, which
presents a high sensitivity, is directly proportional to the partial
pressure, and therefore to the concentration, of NO in the sample.
The optimization of NO selectivity and sensitivity from the
exhaled breath sample relies on catalyst and electrolyte composi-
tion with a complex arrangement of diffusion barrier membranes
and a specific chemical filter system.
Several electrochemical or infrared sensor devices are com-
mercially available: NIOX VERO (Circassia, Oxford, UK),
NObreath (Bedfont Scientific Ltd, Kent, UK), Medisoft (Hypair,
Dinant, Belgium) and Vivatmo pro (Bosch, Waiblingen,
Germany).
The NIOX VERO device is hand-held and portable (less than
1 kg), and can be used for both adults and children [35]. It is pre-
calibrated, designed to ensure a service- and calibration-free sys-
tem, with a sensor that needs replacing between 100 and 300 meas-
urements. Patients have to produce a 10-second exhalation of
breath at an exhalation pressure of 10-20 cmH2O in order to main-
tain a stable flow rate of 50±5 mls-1. A calibrated electrochemical
sensor evaluates the final 3 s of exhalation expressing the result in
ppb in the 5-300 ppb range. The NObreath is a monitoring device
that requires 12 seconds of exhalation of breath in adults and 10
seconds in children. It weighs approximately 400 g, including bat-
teries, which last for up to 120 procedures. As the instrument does
not have a set lifetime, it is strongly suggested that the sensor cells
be replaced every 2 years [35]. The Medisoft device is semi-
portable (weighing approximately 10 kg), and allows for repeat-
able analysis of exhaled NO using an internal sample bag for off-
line measurements. It has a software package that provides a step-
by-step, on-line quality control. The measurement range is 0-600
ppb. The NO cells are long lasting, typically 24 months or longer.
The Vivatmo-PRO device is a portable device with an infrared sen-
sor, which gives a rapid response and may not require storage of
the sample in a chamber. In a recent study it has been showed a
good correlation among some of these devices although the abso-
lute exhaled NO measurements may differ to a clinically relevant
extent [36]. Table 1 summarizes the performance characteristics of
the most representative FENO analysers.
Recently, the use of optical sensors based on different laser
technologies and detection methods has been developed for meas-
uring of NO concentrations [37]. Schematically, these sensors
include a laser source that produces light that interacts with gas
molecules, a gas cell containing the sample to be analyzed, and,
finally, the detection system. For NO detection, the light source in
the optical sensors must probe at the fundamental and strongest
absorption band, centered in the mid-infrared region at 5.3 μm
ranging from 5.1 to 5.7 μm.
Previously, the main limitation of the laser-based NO sensors
in this spectral range was the interference from several other gases,
such as CO2 and H2O. Hence, only specific absorption NO lines
could be targeted, requiring only sensors that could generate the
specific light spectra to be used. 
Other methods are being developed, based on new technolo-
gies, like the smart solid-state microsensors [38]. The optical sen-
sor can be used to detect low levels of NO concentration, utilizing
laser technology to measure the decrease of light intensity due to
absorption by NO; several laser-based sensors have been devel-
oped to detect also 0.3 ppb of NO within 1 s [39-42].
The American Thoracic Society (ATS) and the European
Respiratory Society (ERS) have agreed on a highly standardized
procedure for measurements of lower respiratory tract exhaled NO
[43]. According to the guidelines for FENO measurement in adults,
a single breath sample is instantly analyzed as the subject performs
a breathing maneuver. The subject makes an inhalation to total
lung capacity (TLC) with scrubbed air, not to contaminate the sam-
ple with possibly high NO from the environmental air, and then
Table 1. Performance characteristics for representative FENO
analyzers.
Characteristics     Chemiluminescence    Electrochemical     Laser
Weight                                           40 kg                                   1 kg                         
Sensitivity                                  < 1ppb                              >5 ppb                 1 ppb
Response time                            <1 s                                  >10 s                     1 s
External calibration                    Yes                                     No                        No
Price                                           50 kEUR                             4 kEUR            >100 kEUR
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exhales for 10 s at a specified 5-20 cmH2O pressure. This pressure
is necessary to ensure the closure of the soft palate, minimizing the
risk of contamination of the exhaled NO from the paranasal sinus-
es, where NO concentrations are very high. The guidelines also
recommend an exhaled flow of 50 ml/s (FEno50), based on the
hypothetical assumption that the region of interest for the NO
excretion is within the lower parts of the airways. This relates to
the reasoning that the airways are considered similar to a basic tub-
ing system through which the expired air is led. If there is no NO
depletion within the airway walls during the air passage, a steady
state condition and thereby a stable exhaled concentration level
(plateau) is reached, corresponding to the chosen exhalation flow
rate. The exhalation flow rate can influence the exhaled concentra-
tion level, with low flows resulting in higher levels and vice versa.
A normal FENO concentration in healthy adults is in the 10-20 ppb
range. In inflammatory diseases such as bronchial asthma, not
treated with anti-inflammatory medication, the exhaled NO values
can reach more than 100 ppb.
Interpretation of FENO results
FENO values can be influenced by several non-disease-related
factors, thus filling in a questionnaire for NO measurement is rec-
ommended [44]. Confounding factors could be related to the
patient, like genetics, sex, weight and height, diet (i.e., coffee) or
taking drugs such as anti-inflammatory medications; also current
smoking and atopy seem to influence FENO levels [45,46]. Allergen
exposure is associated with higher levels of FENO but they could
decrease during the early phase of allergic response [47]. Smoking
is an important determinant of FENO levels and current smokers
exhibit lower levels of FENO in comparison to ex-smokers and
never smokers [48]. Both active and passive smoking have effects
on lowering FENO as demonstrated in healthy adults and in both
adults and children suffering from asthma, regardless their allergy
status [49]. Different mechanisms are suggested for explaining the
reduced FENO in smokers such as downregulation of NO synthetase
by NO from cigarette smoke, increased breakdown of NO or lack
of the required supply of tetrahydrobiopterin [50]
FENO could be influenced also by viral respiratory infections
[43]. Age seems to be important too, especially in children [51],
but correlation between age and sex has still to be defined [52-54].
Recently, also ethnicity seems to have a role in FENO results,
impacting clinical management [55-57].
Moreover, there are also technical confounding factors in FENO
measurement, like the NO analyzer used [58], measurement tech-
nique, exhalation flow rate or nasal NO contamination. Spirometry
could also influence FENO results, thus it should not be performed
first [43]. FENO could increase due to bronchodilation and it could
decrease due to bronchoconstriction [47,59]. Over-distension dur-
ing a profound inhalation can affect FENO levels also because the
patient may not have control over exhalation flow rate [44]. Thus,
it is mandatory to correctly interpret FENO results in each patient,
referring to the clinical context in which the test is being done; it
is also important to report the device used to make FENO measure-
ment, how many measurements have been made and the flow rate
(50 ml/s for approved FDA devices) [43]. All the measurements
performed can be included but at least the mean value should be
reported [43]. 
Reference values have been described for FENO in adults
[51,52,60,61] and children [59,62-64]. In clinical practice, FENO
<25 ppb in adults (<20 ppb in children) is considered the normal
value. FENO levels between 25-50 ppb in adults (20-35 ppb in chil-
dren) should be contextualized within the clinical context [43]. 
The eosinophilic asthma phenotype is characterized by sputum
eosinophils ≥3% and identifies patients with a good response to
corticosteroids and T2 immunomodulators. FENO values >50 ppb
(>35 ppb in children) are likely connected with airway
eosinophilic inflammation and this data may be used to predict a
response to anti-inflammatory therapy, while low FENO <25 ppb
(<20 ppb in children) correlates with less eosinophilic inflamma-
tion and responsiveness to corticosteroids [43]. Diagnostic FENO
cut point in well controlled asthma is usually indicated by normal
values [65]. FENO >30 ppb was associated with uncontrolled asth-
ma [66].
According to GINA guidelines, following the diagnosis of
severe asthma, FENO ≥20 ppb is considered the cut-off characteriz-
ing Type 2 inflammation severe asthma and it is used to assess this
asthma phenotype, together with other markers like blood and spu-
tum eosinophils [1]. Is has been suggested a FENO cut point of 21
ppb that best fits ≥3% sputum eosinophils in corticosteroid-naive
patients [67]
Reference values are meant to be used as a general guide,
mindful that they can have significant changes in different patients
[1,43]. 
Very few data from studies analyzing clinically important
change of FENO in individual patients is available [62,68-73] and
different are the results depending on the considered outcome.
Considering simply the within-subject coefficient of variation, in
healthy subject is approximately 10% (corresponding to a raw
change up to 4 ppb) [62,68] while it increases to about 20% in
patients with asthma [71-73], therefore leading the ATS experts to
recommend a change of at least 20% to indicate a significant rise
or fall in FENO over time or following an intervention [43]. If the
considered outcome is the transition from good control to poorly
controlled asthma, a Minimal Clinically Important Difference
(MCID) ranging from 16 ppb to 25 ppb (corresponding to an up to
60% increase from baseline) has been demonstrated [71-73]. On
the other hand, considering the change in FENO during an acute
event, the increase of values has been described as 50% higher in
acute asthma attacks compared with when stability was restored
[70], and up to 150 ppb during exposure to a relevant allergen
[74,75] or acute infection.
Extended nitric oxide analysis
The measurement of exhaled NO at just one exhalation flow
rate does not allow identification of NO production sites within the
respiratory system. Therefore, mathematical models have been
created to calculate the production within lung. George et al. [76]
and Hogman et al. [77] have extensively reviewed the different
models. When the exhaled NO at different flow rates is detected in
breath sampler, the NO production sites in the respiratory system
can be calculated. In particular, the NO flux from the airway wall
to the lumen (JawNO) and fraction of NO in the gas-phase alveolar
region (CANO) can be calculated when NO measurements are
acquired at multiple high flow rates. Additional mathematical cal-
culations with NO measurements obtained at both low and high
flow rates can give the airway tissue concentration of NO released
by the rigid conducting airway system (CawNO) and the transfer
factor indicating the total airway compartment diffusion capacity
(DawNO). Hence, extended NO analysis can shed light on the NO
production sites of the respiratory system in patients.
The clinical application of measuring FENO at different flow
rates is yet limited to some research setting, however information
on the contributions of the bronchi (bronchial NO flux) and the
peripheral lung (alveolar NO concentration) to exhaled NO is
intriguing [78.]
Increased alveolar NO concentration has been reported in
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severe, nocturnal and treated asthma [79] while NO flux from
bronchial lumen (J’awNO) was associated to cough variant asthma
and non-asthmatic eosinophilic bronchitis [80]. 
In all chemilumiscence analyzers, expiratory flow rates can be
modified by resistors, allowing an extended NO analysis. On the
other hand, most electrochemical sensors are not suitable for mul-
tiple flow analysis. An exception is the Medisoft that allows eval-
uation of exhaled NO at multiple flow rates.
FENO in asthma diagnosis
As the GINA guidelines suggest [1], FENO cannot be used as
the only parameter for ruling in or ruling out a diagnosis of asthma.
Its values are higher than normal in asthmatics that are character-
ized by Type 2 airway inflammation, and, as previously reported,
several factors can affect FENO levels (smoke, bronchoconstriction,
viral respiratory infections). 
On the other hand, the British National Institute for Health
Care Excellence (NICE) guidelines [81] recommend FENO testing
in combination with other diagnostic options to help diagnose asth-
ma in adults and children when diagnosis is unclear (i.e., in case of
normal lung function), and in those for whom, after initial clinical
examination, an intermediate probability of having asthma is pres-
ent or in those with confounding factors as obesity, anxiety, etc…
[82]. FENO measurement is recommended by NICE also as an
option to support asthma management in people who are sympto-
matic despite using inhaled corticosteroid (ICS) treatment.
FENO measurement could also be used in differentiating
Cough-Variant Asthma (CVA) from other causes of chronic cough
[83-86], to distinguish pre-school wheezing phenotypes and to
assess the risk of later asthma or impaired lung growth and lung
dysfunction in children [87].  
According to the available literature, high FENO values increase
the probability of asthma diagnosis, while a negative test does not
necessarily exclude asthma [43]. Data from secondary care
patients showed a sensitivity of 43–88% and specificity of 60–92%
[88] for diagnosis of asthma. The Positive Predictive Value (PPV)
and Negative Predictive Value (NPV) were 54-95% and 65-93%,
respectively [43]. Thus, around 1 in 5 people with a positive FENO
test will not have asthma (false positives), and 1 in 5 people with a
negative FENO test will have asthma (false negatives).  However,
even if data on FENO specificity and sensibility are heterogeneous
and could vary between studies, FENO seem to have higher speci-
ficity than sensitivity for the diagnosis of asthma, so FENO meas-
urement is better at ruling in rather than to ruling out asthma diag-
nosis [89]. Sensitivity but not specificity could vary significantly
among different FENO devices [89]. Specificity is optimized if
higher FENO cut-off is used. ATS guidelines show that FENO >36
ppb had a sensitivity of 78% and a specificity of 72% for sputum
eosinophilia, while a FENO <26 ppb has a negative predictive value
of 85% [43]. 
FENO and asthma comorbidities
Atopy
Atopy, defined as sensitization to common inhalant allergens,
in the absence of allergic diseases, such as rhinitis, has been con-
sistently reported to be associated with increased FENO values,
when compared to values observed in non-atopic control subjects,
in children, but not in adults [90]. In children, exhaled NO corre-
lates with the degree of IgE sensitization, in terms of both the num-
ber of positive skin-prick tests [91] and IgE-antibody concentra-
tions [92]. Recently it has been shown that increased levels of
exhaled NO in adolescents, 12-15 years old, precede incident self-
reported allergic symptoms to cat and dog within four years [93]. 
Rhinitis
FENO values are generally reported to be higher in adults with
allergic rhinitis (AR) when compared to healthy controls and
patients with non-allergic rhinitis (NAR) [94]. As up to one third
of patients with rhinitis may have asthma, it is interesting to report
that AR with/without asthma had significantly higher FENO levels
than patients with NAR without asthma, while subjects with NAR
and asthma exhibited elevated FENO levels, similar to AR [95].
Natural pollen exposure was found to cause a significant FENO ele-
vation in allergic individuals. Thus, IgE-mediated allergy has been
reported to be responsible for elevated FENO [96]. FENO values that
were lower in AR compared with asthma were shown to reach sim-
ilar levels after allergen exposure [97]. In patients with rhinitis and
asthma-like symptoms, the presence of asthma was associated with
higher FENO values [98]. In a consecutive series of patients referred
to an allergy clinic for chronic persistent rhinitis symptoms, airway
inflammation, evaluated by increased values of FENO, and diagno-
sis of asthma were significantly more prevalent in patients with AR
and chronic rhinosinusitis (CRS) compared to patients with non-
allergic rhinitis [99]. One every four subjects with allergic rhinitis
and very high FENO values (>50 ppb) have been shown to develop
asthma at follow up according to a recent report [100]. 
Chronic rhinosinusitis
Chronic rhinosinusitis is classified into CRS with nasal polyps
(CRSwNP), characterized by eosinophilic inflammation and CRS
without nasal polyps (CRSsNP). Asthma is more frequently seen in
CRSwNP patients than in CRSsNP patients. FENO, blood
eosinophil counts, number of eosinophils in nasal polyps, and total
IgE are generally all higher in CRSwNP patients than in CRSsNP
patients. FENO values in CRSwNP patients without asthma showed
significantly higher FENO values than CRSsNP patients without
asthma, while no significant difference in FENO was seen between
patients with CRSwNP with and without asthma [101]. The pres-
ence of nasal polyps in patients with CRS was associated with
increased asthma prevalence as well as increased FENO levels.
Respiratory symptoms without bronchial hyperresponsiveness
were associated with eosinophilic airway inflammation and
increased FENO only in patients with nasal polyps [102], suggesting
eosinophilic airway inflammation even in patients without asthma.
FENO and asthma control
Its intrinsic feature as a biomarker of the underlying T2-medi-
ated airway inflammation in asthmatics [103], its ability to predict
asthma exacerbation [104,105] and the prompt reduction after anti-
inflammatory treatment initiation [106,107] theoretically make
FENO as a promising biomarker of poor asthma control.
Many studies investigated this aspect both in children and in
adults with contradictory results reported so far: some Authors
reported higher FENO levels in uncontrolled or partially controlled
asthmatics both in adults [64,108,109] and children [110-112],
while others failed to find such a correlation [113-119]. A recent
metanalysis including many of these studies concluded that there
is only a weak correlation between FENO levels and current asthma
control [120].
This apparent contradiction between the promising role of
FENO as a biomarker of asthma control and the reported results may
be explained looking at the clinical characteristics of patients
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included into the different studies: in fact, a better correlation
between high FENO levels and poor asthma control was seen in
patients not on regular treatment for asthma [111,112,121], while
patients regularly treated with ICS seem to demonstrate weaker or
no correlation between FENO and asthma control [111-113,116-
119,121]. It is also possible that the presence of sino-nasal comor-
bidities (such as allergic rhinitis or chronic rhinosinusitis with
nasal polyps), which are frequently associated with asthma, may
have an influence on the correlation between FENO and asthma
control, as they may independently increase FENO levels [99,102]. 
The performance of FENO as a biomarker of asthma control
increases when its assessment is combined with lung function
parameters [122-123], when it is used to predict the future risk of
losing asthma control [124-128], or when its increase in a given
time is considered as a marker of loss of asthma control [119].
It is therefore suggestable that combined measurement (at first
clinical evaluation and during regular follow ups) of FENO and lung
function, which are both easy to obtain in clinical practice, may
help clinicians to predict the achievement of asthma control after
treatment initiation. Moreover, considering the easiness of FENO
assessment even in pre-school children, its use to determine asth-
ma control can be reasonable particularly when lung function and
self-reported control level are difficult to obtain [110]. 
FENO and response to asthma treatments 
Glucocorticoids are known to reduce eosinophilic inflamma-
tion that characterizes most of the asthma phenotypes; therefore,
FENO has the potential properties to be the perfect tool for monitor-
ing the response to inhaled and/or systemic corticosteroid treat-
ments in asthmatic patients. 
In steroid-naïve patients, FENO has been shown to be a reliable
predictor of responsiveness to ICS, with high levels associated
with favorable response to the treatment [105, 129-131]. Higher
baseline FENO levels were indeed able to predict ICS response in
terms of improvement of lung function both in adults [132-134]
and children [135], and in terms of reduction of symptoms
[133,134] (at least in eosinophilic phenotypes) and improvement
of asthma-related quality of life [133]. The study by Cowan et al.
[134] showed that, despite FENO was able to predict the improve-
ment of asthmatic symptoms only in patients with eosinophilic
asthma after a short course of 4 weeks of ICS, its high baseline lev-
els were associated to a significant reduction in bronchial hyperre-
sponsiveness also in patients with non-eosinophilic asthma, sug-
gesting that these subjects may need longer ICS treatment to obtain
also a clinical response associated with the prompt lung function
improvement. A further subanalysis of the same study confirmed
the same results [136].
The ability of FENO to predict ICS response could be even more
clinically relevant when evaluating patients with non-specific res-
piratory symptoms (such as isolated cough) and not already clearly
diagnosed with asthma [133,137]. A double-blind randomized
placebo-controlled trial published by Price et al. [133] showed that
higher baseline FENO was associated with better response to ICS in
patients with undiagnosed, non-specific respiratory symptoms.
Interestingly, in this study FENO performance in predicting ICS
response was superior than baseline lung function assessment,
blood eosinophil count and clinical opinion of asthma. This study
confirmed, using a more robust study design, previous similar
observation in single-blind design and with limited number of
patients [137]. 
More controversial is the effect of leukotriene-receptor antag-
onists (LTRA) on FENO, as some studies showed a prompt and sus-
tained reduction of it [138-143], while others failed to find this
association [144-146]. Further studies are therefore needed to clar-
ify if this class of drugs affects FENO.
In any case, when a response to ICS and/or LTRA has been
found, FENO decreases rapidly, generally more quickly than other
asthmatic features, such as lung function parameters, symptoms or
airway hyperreactivity [106]. This rapid response to anti-inflam-
matory treatments, together with similarly rapid increase before
worsening of asthma control and exacerbations [104,147] led
researchers to investigate the potential therapeutical strategies
based on tailoring the treatment level according to FENO assess-
ment [131].  A recent metanalysis [131] combining data from three
previously published Cochrane reviews [148-150], highlighted
that tailoring of asthma therapy based on FENO results in a signifi-
cant reduction of exacerbations in adults and a similar tendency in
children, compared to guidelines-based therapeutical strategies;
interestingly, these results were obtained without an increase need
in ICS dose, reinforcing the benefit that may be achieved from a
FENO -based strategy for tailoring asthma therapy.
FENO and adherence to treatment
A proportion of patients with asthma remains symptomatic
despite prescription of adequate treatment and they should be dis-
tinguished into two categories: patients with possible severe asth-
ma (“difficult-to-control” asthmatics) and those with other causes
of poor asthma control (“difficult-to-treat” asthmatics) [151];
among these causes, nonadherence to ICS is a major determinant
of poor asthma control and treatment failure accounting about 50%
of those who had been prescribed long-term treatment [152].
Distinguishing patients with difficult-to-control asthma who may
respond to ICS if properly addressed from those really affected by
refractory asthma is an important clinical challenge. 
FENO has been largely investigated as possible tool to identify
nonadherence [68,124,153-159]: elevated FENO levels were con-
stantly associated with nonadherence, despite the heterogeneity of
methods used to assess the adherence to treatment, both in children
and adults; this ability to identify poorly adherent patients was
constantly reported to be greater for FENO than for other parameters
such as lung function or patient-reported symptoms. Fewer are the
reports of poor correlation between FENO and adherence to treat-
ment, probably due to the very small number of patients enrolled
[159].
McNicholl et al. [130] developed the so-called “FENO suppres-
sion test”, a practical objective procedure for assessing nonadher-
ence in difficult-to-treat asthma; they enrolled asthmatic patients
with persistently elevated FENO despite treatment and administered
them inhaled budesonide 1600 mg for 7 consecutive days under
their direct observation. FENO was daily measured for 8 days, then
weekly for 4 weeks to test its suppression after directly observed
inhaled corticosteroid (DOICS) treatment; if FENO persisted to be
higher than 40 ppb after seven days of DOICS, intramuscular tri-
amcinolone 80 mg was administered, to demonstrate FENO respon-
siveness to high-dose systemic corticosteroids. A composite meas-
ure comprising prescription records, adherence interview, blood
testing, and inhaler technique, was used to assess nonadherence.
Using this study design, they were able to reveal that suppression
of FENO after DOICS had a sensitivity of 67%, a specificity of 95%
and a positive predictive value of 92% in identifying nonadherent
patients and differentiating them from patients with proper severe
asthma. A subsequent study from the same group of Authors
demonstrated that the FENO suppression test is applicable in a rou-
tine clinical care of reference centers for severe asthma, with the
help of an integrated remote monitoring technology specifically
developed [158].
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FENO in severe asthma
Severe asthma is well known to be a heterogeneous disease
that comprises multiple factors and that predisposes approximately
10% of asthmatic patients to suffer daily symptoms and acute
exacerbations despite the intake of high-dose inhaled corticos-
teroids (ICS), oral corticosteroids (OCS), and other controllers [5].
Recently, identification of severe asthma mediated by Type 2
inflammation has resulted in the successful launch of several bio-
logic therapies that target specific inflammatory phenotypes.
Several biomarkers have been proposed for the Type 2 severe asth-
ma, such FENO, eosinophils in blood or in sputum and periostin.
The last GINA guidelines confirmed the role of FENO as a use-
ful, easy to perform and cost-effective phenotyping test for severe
asthma management [1]. The possibility of refractory Type 2
inflammation should be considered if FENO ≥20 ppb is found while
the patient is taking high-dose ICS, together with blood
eosinophils (>150/µl), sputum eosinophils (>2%) or allergen-driv-
en asthma; blood eosinophils and FENO should be repeated up to 3
times, on lowest possible OCS dose, before excluding Type 2
severe asthma. 
FENO ≥20 ppb may also predict an increase in exacerbations.
FENO demonstrated itself to be the strongest predictor of exacerba-
tion in severe asthmatic patients treated with high dose ICS and
OCS when compared to peripheral blood eosinophils and periostin
[104]. 
A recent study by Price and collaborators showed that in a pop-
ulation of asthmatic in ICS treatment, the combination of high
FENO and high blood eosinophil count (≥300 cell/µl) was associat-
ed to a significant increase in severe exacerbation rate, up to four
times or twice if categorized in FENO≥50 ppb or FENO≥35 ppb
respectively compared to patients with non-high FENO and non-
high blood eosinophils [159]. Furthermore, several studies support
the use of FENO as a marker to guiding OCS increase or escalation
in severe as well as in mild-moderate asthmatics [160,161]. If
patient has good response to Type 2 targeted therapy, internet-
based monitoring of symptom control and FENO may help the clin-
ician to decide if gradually decreasing or stopping OCS [1]. On the
other hand, the international ERS/ATS guidelines suggest that clin-
icians do not use FENO to guide OCS therapy in adults with severe
asthma [5]. Recently, FENO has also started to be proposed as a pre-
dictor of efficacy of biologic therapies. The story in this direction
started with the EXTRA study [163] in which FENO showed to be
able to identify responders to omalizumab. GINA guidelines [1]
also confirm that FENO ≥20 ppb, associated with blood eosinophils
≥ 260/μl, allergen-driven symptoms and childhood-onset asthma,
predicts a good response to anti-IgE biologic treatment. 
Several later studies supported the role of FENO as a good pre-
dictor of efficacy to omalizumab [164,165]. However, if FENO
seems to well identify responders to omalizumab, no efficacy has
been demonstrated for alveolar concentration of nitric oxide that
did not modify its concentrations after treatment with omalizumab
[166]. On the other hand, contrasting data are available on FENO as
a marker of good response to mepolizumab. In the DREAM study
[167], no statistical differences were found in FENO after treatment
with mepolizumab compared to baseline values, suggesting that
FENO may not be responsive to modulation through IL-5 pathway.
Accordingly, with the DREAM study, Farah et al. demonstrated
that treatment with mepolizumab improves small airway function,
but not spirometry and FENO [168]. 
FENO has also been evaluated in the identification of patients
eligible for dupilumab, a human anti IL-4 and IL-13 antibody.
Castro et al. [169] found that the subgroup of severe asthmatic
with higher FENO treated with dupilumab experienced a more sig-
nificant clinical efficacy in terms of reduction of exacerbation and
functional improvement compared to asthmatic with lower FENO.
Wenzel et al. [170] also confirmed the best role of FENO, among
other Type 2 inflammation biomarkers, in predicting the best
responder to dupilumab.
Lebrikizumab, a humanized anti IL-13 antibody, showed a
marked reduction in FENO values correlated to improvement in
asthma control compared to placebo [171], while tralokinumab,
another anti IL-13 humanized antibody, showed controversial
results regarding its utility in reducing asthma exacerbation rate in
relation with FENO values: in the STRATOS 1 study high-FENO
group (>37 ppb) showed a lower exacerbation rate versus placebo,
while in the STRATOS 2 study this finding was not confirmed
[172]. In addition, in the MESOS trial tralokinumab showed a sig-
nificant reduction in FENO values in moderate-to-severe asthmatic
patients [173].
Finally, treatment with tezepelumab, a humanized antibody
targeting thymic stromal lymphopoietin (TSLP), was associated
with a substantial and persistent decreasing in blood eosinophil
counts and FENO levels [174].
FENO, as well as eosinophils, are biomarkers easy to measure
in clinical practice and their combined evaluation can identify
patients with frequent exacerbations and stratify the appropriate
therapy for Type 2 inflammation-predominant severe asthma
[175].
FENO in childhood asthma
The first reports about the high level of FENO in children with
asthma date from 1997 [176,177]. FENO represents an interesting
way to monitor airway inflammation, because of its non-invasive
nature and the relatively easy use. In fact, measurement can be
obtained in most children starting from 5-6 years old and results
are available in a few minutes. 
Recommendations for FENO measurements in children have
been published and are used worldwide [30,178]. FENO measure-
ment is performed with a deep inhalation through the mouth and
slow exhalation, with feedback of the flow rate for the subject.
Velum closure is mandatory and achieved by using a positive pres-
sure of 5-20 cmH2O against exhalation. An approved measure is
one in which the flow rate is within 10% of the target value, i.e. 45-
55 ml·s−1 [30,170]. 
FENO levels correlate with eosinophilic counts in induced spu-
tum (5) and bronchoalveolar lavage fluid as well as with
eosinophil infiltration of the airways and peripheral eosinophilia,
mainly in atopic children [179,180]. Correlations were also found
with serum total IgE, serum eosinophil cationic protein (ECP) and
the number of positive skin prick tests [179-181]. Consequently,
FENO is considered a marker of the most common asthma endotype
in children, characterized by Th2-mediated airway inflammation,
eosinophilia and responsiveness to inhaled steroids [182].
Moreover, some studies suggest that low FENO levels predict a non-
eosinophilic asthma phenotype better than high levels can predict
an eosinophilic one [183]. It has also been suggested that FENO can
help us to identify early-onset asthma among preschool-age chil-
dren with recurrent wheezing [179,184,185]. At last, several stud-
ies demonstrated that FENO is increased in atopic children with and
without asthma, suggesting that atopy and asthma could be cofac-
tors in determining elevated FENO levels [181,186,187]. It has been
also established that baseline FENO levels are elevated in children
with exercise-induced bronchoconstriction and relate with the
degree of post-exercise bronchoconstriction, suggesting that FENO
may be a predictor of airway hyperresponsiveness to exercise,
especially in asthmatic children sensitive to indoor allergens [188].
On these bases, it has been proposed a role of FENO in asthma
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diagnosis in children.  Sensitivity and specificity of FENO measure-
ments were showed to be acceptable to discriminate asthma from
other non-asthmatic conditions in previous clinical studies [189],
though normal FENO levels do not exclude the diagnosis of asthma,
especially in non-atopic subjects.  In fact, FENO levels of atopic
asthmatic are higher than those of non-atopic asthmatics [190].
Furthermore, it has to be considered that there is a large range in
FENO levels among children, which may reflect the natural hetero-
geneity in baseline epithelial nitric oxide synthase activity with the
contribution of other non-eosinophilic factors. 
Normal values of FENO and feasibility in children have been
assessed, showing that FENO levels in healthy children are below
15 to 25 ppb [60,191]. These values range is the result of several
factors: age, gender, height, ethnicity, allergic sensitization, serum
total IgE, infections, a nitrate rich diet, exercise, smoking, environ-
mental nitric oxide, time of the day, season and environmental pol-
lution [182,192-194). A systematic review and meta-analysis on
eight current diagnostic accuracy studies, including 2,933 cases of
diagnostic performance of FENO in children with asthma, indicates
a FENO values range from 19 ppb to 25 ppb as the best cut-point to
diagnose asthma [195]. This range showed the equal highest
Youden’s index (sensitivity + specificity -100). 
In a study performed in preschool children, FENO was higher in
those with a frequent recurrent wheeze and a stringent index for the
prediction of [asthma asthma predictive index (API)] than in those
with a loose index or those with recurrent or chronic cough but no
history of wheeze [196,197]. Furthermore, in infants with eczema
but not yet wheezing, exhaled nitric oxide was shown to be capable
to provide important insights into the risk of asthma later in child-
hood and its airway characteristics [198]. The body of these data is
in favour of the idea that objective measurement of FENO in addi-
tion to the clinical characterization may improve the possibility of
defining disease presentation and of predicting disease progression
in preschool children. 
Therefore, currently, FENO may be regarded as a potential com-
plementary tool in asthma diagnosis pathway in children.
There is also a strong interest to use FENO as a guide for asthma
treatment, considering that FENO reflects airway inflammation. In
fact, in some studies FENO is validated as a useful tool both in diag-
nosing and managing children with atopic asthma [60]. Data sug-
gest that using FENO to tailor the dose of ICS cannot be recom-
mended in routine clinical practice, because of the danger of exces-
sive doses of treatment without significant changes in clinical out-
comes. In fact, two meta-analyses of paediatric studies showed that
FENO monitoring lead to increased use of ICS, without significant
influence on lung function outcomes (FEV1 levels) compared to
conventional management [199,200]. Actually, a guideline-based
approach still remains essential [199]. It has been suggested that
FENO may be more appropriate for tapering, rather than for step-
ping up anti-inflammatory treatment and could be used mainly as
an indicator of the child’s compliance with the prescribed therapy
[182]. In fact, the relatively rapid shift of FENO levels after steroid
treatment suggests its utility in monitoring adherence to and
response to therapy [43,201].  
For these reasons different authors suggested to use FENO to
rationalize corticosteroid therapy in asthmatic patients, together
with the traditional clinical tools (history, physical examination
and lung function tests) [43]. Nevertheless, the issue to consider
FENO as a clinical tool to manage asthma treatment in children is
still under debate [202]. 
Some previous studies showed that FENO increased in uncon-
trolled asthmatic children, especially during exacerbations [202].
In particular, a study, in which 22 children allergic to mites under-
went twice-daily fractional exhaled nitric oxide measurement
before, during and after period of natural exposure to mite aller-
gens, observed significant differences between the mite-free base-
line FENO level and FENO levels measured during natural mite
exposure and after natural mite exposure [203]. Moreover, six chil-
dren reported asthma symptoms during the mite exposure, and an
increase in FENO was observed in each case [203].
The usefulness of FENO for monitoring children with moderate-
to-severe asthma is still unclear. In fact, studies aimed to evaluate
FENO usefulness as a predictor of asthma exacerbations show con-
flicting results. Moreover, a consensus about the optimal FENO cut-
point level to define high risk of exacerbation still lack. Cabral et
al. showed no benefits in tapering ICS doses in atopic children by
monitoring FENO levels, suggesting that this tool has a limited
value as a predictor of asthma exacerbations [204]. Conversely,
some data reported that FENO might be helpful in predicting and
preventing exacerbations. In a study based on daily FENO values
and symptom scores over 192 days in 41 atopic asthmatic children,
Stern et al. have demonstrated that fluctuation in FENO values and
their cross-correlation to symptom scores give information on
asthma severity and control [205]. They found that the majority of
subjects had the strongest positive relationship between FENO val-
ues and symptom scores on the same day. Children who had a
severe or moderate exacerbation had a stronger positive cross-cor-
relation between FENO values and symptom scores, suggesting that
concordance of FENO values and symptom scores is an indicator of
increased risk of exacerbation [205]. In another study, Gagliardo et
al. found a significant correlation between FENO levels and other
markers of inflammation, such as sputum eosinophilia and IL-8,
and the number of severe exacerbations in asthmatic children
[206]. Van der Valk et al. collected longitudinal daily FENO mea-
surements in relation to exacerbations in atopic asthmatic children
[207]. They have found changes in FENO prior to moderate, but not
severe exacerbations. Probably, moderate exacerbations are pre-
ceded by increased eosinophilic airway inflammation and the level
of cross-correlation between FENO levels and symptoms could
identify children at risk for exacerbations. However, the study
sample size was small and the therapeutic intervention with ICS
could have modified the association between FENO and exacerba-
tions [207]. At last, in a study based on forty-two children with
confirmed asthma, Chang et al. has found that FENO values were
associated with an increased risk for subsequent loss of asthma
control 4 weeks after ICS withdrawal (40). Moreover, subjects
with high FENO values had an earlier LAC respect subjects with
normal FENO [208]. Their findings suggest that FENO values may be
useful to predict subsequent loss of asthma control among asymp-
tomatic children after ICS interruption. In this setting, FENO level
may contribute for clinical follow up decision during childhood
asthma after ICS withdrawal. Discordant data were found also
about the correlations between FENO and Asthma Control Test
scores, both in adults and in children [209]. A study on 200 asth-
matic children (47 of them with newly diagnosed asthma and with-
out any regular controller therapy) has pointed out that the assess-
ment of asthma control by Children-ACT questionnaire in children
is significantly related to the level of FENO in newly diagnosed
patients, but not in those already under regular follow up [111].  
In conclusion, due to the complex nature of the disease, asthma
control in children needs more than only one item in assessment and
both physician evaluation and other objective testing are necessary.
FENO may provide useful information about airway inflammation,
playing a complementary role in the management of asthma.
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FENO in respiratory diseases other than asthma
Chronic obstructive pulmonary disease 
The clinical value of FENO measurements in patients with
established chronic obstructive pulmonary disease (COPD) is not
presently clear.  According to a recent systematic review and met-
analysis [210] patients with stable COPD had a mild elevation of
FENO levels compared to healthy controls, with FENO levels much
higher in ex-smokers than in current smokers. No association was
found between FENO levels and exacerbated COPD. Some studies
show that, at least in the short term, the response to corticosteroids
is likely to be greater in patients with COPD who also have elevat-
ed FENO [211]. A raised FENO had been shown to predict FEV1
response to ICS in COPD [212,213]. 
In a significant number of patients, an overlap syndrome com-
prising features of both asthma and COPD is found [214]. The air-
way inflammatory cell infiltrate may be mixed, including
eosinophilic inflammation. Asthma-COPD overlap (ACO) is char-
acterized by persistent airflow limitation and several manifesta-
tions usually associated with both asthma and COPD. A
GINA/GOLD document on ACO recommended that both FENO
and blood eosinophils be used as inflammatory biomarkers for dif-
ferentiating ACO from COPD [215]. According to a recent study,
for patients naïve to ICS, FENO level >25.0 ppb combined with a
blood eosinophil count >250 cells/μl showed high specificity
(96.1%) for differentiating ACO from COPD [216]. 
Obstructive sleep apnea 
Obstructive sleep apnoea (OSA) is a sleep disorder that may
lead to metabolic abnormalities and increased cardiovascular risks.
Airway and systemic inflammation has been proposed to have a
central role in the pathophysiology of OSA [217]. Inflammation
involving the nose, the uvula, the soft palate and the pharyngola-
ryngeal tract promotes and aggravates oropharyngeal inspiratory
muscle dysfunction, upper airway narrowing and collapsibility. A
slightly increase in levels of NO were detected in the exhaled air
of OSA compared to healthy subjects, generally between 20 and 25
ppb, it is more evident in nonsmoking OSA and after sleep and it
seems to reflect bronchial neutrophilic inflammation [218].
Increased FENO in OSA is not consistently positively related to
the severity of OSA (apnoea / hypopnoea index) thus excluding a
clear role for screening OSA in adults. [219] On the contrary, nasal
NO (nNO) might have a greater value that FENO in the fact that
correlates to AHI and time of SpO2<90%, potentially reflecting
upper airway inflammation in OAS patients. A nNO higher that
626 ppb could be recommended for confirming OSA by
polysomnography [220].
Non-asthmatic eosinophilic bronchitis 
Non-asthmatic eosinophilic bronchitis (NAEB) is character-
ized by chronic irritable dry cough, sputum eosinophilia and being
responsive well to glucocorticosteroids [221]. In contrast to asth-
ma, NAEB presents no airflow obstruction and airway hyperre-
sponsiveness [221]. Some reports indicate that FENO levels in
patients with NAEB were significantly higher than those in other
causes of chronic cough [222]. According to a systematic review
and meta-analysis [223] FENO test might not be precise enough to
predict NAEB in non-asthmatic patients with chronic cough.
Hierarchical summary receiver operating characteristic curve
analyses suggested sensitivity and specificity were 72% and 83%,
respectively, with optimal cutoff levels ranging from 30 to 40 ppb.
Even if FENO measurement might not fully replace induced sputum
analyses, the clinical utility of FENO should not be dismissed in the
non-asthmatic population with cough, where FENO may help to
identify corticosteroid-responsive patients among the non-asthmat-
ic population with cough.
Acute eosinophilic pneumonia
Acute eosinophilic pneumonia (AEP) is to be suspected in
patients with progressive and severe dyspnea less 1-2 weeks in
duration and a chest radiograph showing diffuse parenchymal
opacities. At presentation eosinophilia is not present in peripheral
blood, while there is typical BAL eosinophilia (> 25%).  Among 60
subjects prospectively enrolled with pulmonary infiltrates and a
febrile illness and who were clinically suspected to have AEP, the
pretreatment FENO levels of the patients with AEP were significant-
ly higher than those of the patients without AEP. The cut-off value
(23.5 ppb) showed that the maximal area under the receiver oper-
ating characteristic curve predicted AEP with a sensitivity of 87%
and a specificity of 83% [224]. 
FENO measurement has been shown to be useful for differenti-
ating AEP from other types of acute-onset interstitial lung diseases,
regardless of the blood eosinophil levels [225]: forty patients with
a combination of illness ≤4 weeks in duration and diffuse radi-
ographic infiltrates were classified into groups based on the etiol-
ogy; the median FENO value of patients with AEP (48.1 ppb) was
significantly higher than that of the other groups (17.4 ppb in cryp-
togenic organizing pneumonia, 20.5 ppb in hypersensitivity pneu-
monia, and 12.0 ppb for sarcoidosis). The area under the receiver’s
operating characteristic curve (AUC) for FENO to identify AEP was
0.90 with a cut-off of 23.4 ppb [225].
Chronic eosinophilic pneumonia
Chronic eosinophilic pneumonia (CEP) is characterized by
chronic respiratory symptoms, bilateral peripheral lung opacities,
pulmonary eosinophilia, and peripheral eosinophilia. Symptoms and
radiopacities resolve rapidly after corticosteroid treatment, but they
recur frequently after tapering or discontinuing the medication.
FENO levels were measured in 18 patients with CEP at several
assessment points over one year, showing positive correlation with
peripheral eosinophil count [226]. The median FENO levels were
significantly higher in uncontrolled compared to controlled CEP.
The FENO level of 66.0 ppb showed the largest area under the curve
(0.835) for predicting exacerbation of CEP (sensitivity 80%, speci-
ficity 84%). Authors concluded that FENO may be useful for moni-
toring eosinophilic parenchymal inflammation and determining the
appropriate corticosteroid dose in CEP [226]. 
Nasal nitric oxide
As shown by Lundberg et al. in 1995 [226], nasal cavity and
upper airways represent the major source of nitric oxide detected
in the respiratory tract of adult healthy subjects [227]. They found
a continuous nitric oxide synthesis in paranasal sinuses, yielding
very high nitric oxide concentration (3000-25000 ppb) contribut-
ing to that found in nasal air.
The nasal nitric oxide, which represents more than 90% of the
total [228], is produced by all three NOS isoforms that have been
identified in the upper airways in epithelial cells of nasal mucosa,
in parasympathetic neurons innervating nasal vessels, in endothe-
lial cells and in ciliated epithelial cells [229]. Interestingly, the
NOS found in the paranasal sinuses is essentially calcium inde-
pendent [20], a characteristic usually related to NOS-2, but it is
constitutively expressed and resistant to steroids, the latter being
typical features of constitutive NOSs.
Nasal NO can have several physiological functions including the
participation in non-specific host defense against bacterial, viral and
fungal infections [230], preserving a sterile microenvironment with-
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in the paranasal sinuses, regulating cilia motility [231,232] and the
nasal airway resistance to airflow, and entering in the humidification
and warming mechanisms of inhaled nasal air flow [233]. Nasal NO
has also been hypothesized to improve the ventilation–perfusion
ratio in the lungs by the auto-inhalation [231,232], and to act as an
aerocrine messenger between the upper and lower airways [234].
However, none of these actions has been directly associated with the
high levels of NO detected in the nose [19].
As in the lower airways, nasal NO can exert the biological
effects of NO by a direct action [21], although some of its physio-
logical and pathophysiological effects (especially its pro-inflam-
matory actions) are likely to be activated by NO derivatives and
not by the molecule itself. As discussed above, it can form com-
plexes of metal-containing proteins, leading to enzyme activation
or inhibition, or directly interact with high energy free radicals and
modulate other oxidative reactions like lipid peroxidation inhibi-
tion, and limit the generation of pro-inflammatory lipids [21].
Furthermore, the NO indirect effects are mediated by reactive
nitrogen oxide species (RNOS) originating from its interactions
with O2 or O2•– [21].
Differently from lower airways, there are several methods to
measure nasal NO (nNO). Currently, two methods of nNO assess-
ment are recommended: nasal aspiration via one nostril during
velum closure, and nasal exhalation through a tight facemask with
fixed flow [30,43]. In the first method, nNO is aspirated from
patients by the intrinsic suction of analyzer through a line with a
disposable foam olive inserted into one nostril while palate is close
by exhaling through the mouth (20–40 s) into a disposable resistor
(with a resistance of at least 10-cm H2O). Alternatively, nNO is
aspirated while the subject breath holds with the velum elevated.
In this case, a suction pump aspirates air through a nasal olive
placed in one nostril with the subject holding his/her breath after
inspiration to total lung capacity. In the second method, the nasal
exhalation through a tight facemask with a stable fixed flow is
used. The subject starts inhaling NO-free air from the analyzer
through the nose during a full inspiration to total lung capacity, and
then exhales through a tightly fitting mask covering the nose con-
nected to the analyzer. The obtained NO values can be in parts per
billion (ppb) or in nl/min (multiplying nasal NO concentration
(ppb) by the sampling flow rate).
Differently from exhaled nitric oxide, nNO measurements
have been proposed as diagnostic tool in only a few diseases. In
primary ciliary dyskinesia (PCD), nNO is by far the most effective
screening tool [235], with a specificity of 88%, a sensitivity of
100%, and a positive predictive value of 89% for a correct diagno-
sis when using a nNO cut-off concentration of 105 ppb [236]. It
has also been reported that a value of nNO less than 100 ppb or 77
nl/min would strongly suggest PCD [237] and Collins et al. [238]
using the same cut-off found a sensitivity of 93% and specificity of
84%, with a positive predictive value of 42.6% and a negative pre-
dictive value of 99%. 
Some authors suggest that nasal NO measurements could also be
useful in screening for cystic fibrosis (CF) patients, as they present
low levels of exhaled NO [239,240]. However, the NO metabolism
in CF airways is complex and not yet completely understood, and
therefore it is of limited value in the diagnosis of CF.
In analogy with other inflammatory diseases, nNO has been
proposed also for the diagnosis of allergic rhinitis [94,241] and for
the diagnosis, prognosis or treatment evaluation of other sino-nasal
diseases [242,243]. However, as showed by Phillips et al. [244],
data referring to the sino-nasal application of nNO measurements
have produced no clear evidence of clinical relevance, except for
the impact of sinus surgery. A possible explanation is that nNO
measurements in sino-nasal pathologies are currently hampered by
confounding factors such as the continuous gas exchange between
the nasal airway and paranasal sinuses [245], which may affect the
ability to detect alterations in nNO occurring in sino-nasal disor-
ders [246]. However, a very recent study suggests to use nNO also
for differentiate AR patients from healthy subjects and may be sig-
nificantly correlated with nasal symptoms and nasal patency of
rhinitis patients [247]. A few data are consistent with the finding of
lower nNO levels in patients with CRS compared with controls,
and they reported an inverse correlation between nNO level and
CT changes in patients with CRS [248]. Moreover, testing for nNO
was highly predictive of separating CRSwNP , who had the lowest
values, from patients with CRSsNP, and nNO cutoff value of less
than 442 ppb was associated with the best combination of sensitiv-
ity and specificity, with a PPV of 87% and an NPV of 91% in
detecting CRSwNP [242]. A more recent report confirmed the
acceptability of the receiver operating characteristic curves in dif-
ferentiating patients as CRSwNP, CRSsNP, and healthy controls
and the correlation with sinus computed tomography and
Sinonasal Outcome Test Scores [249,250].
The evidence that measurements of nNO during humming
(which is the production of a tone without opening the lips or form-
ing words) are correlated with ostial function [246,251,252], has
led to its potential use as test for osteo-meatal patency. In normal
conditions, humming causes a great increase in nNO (humming
responders), whilst, when there is an obstruction of osteo-meatal
complex, this maneuver does not cause any increase in NO (hum-
ming non-responders). This method may represent a suitable non-
invasive test to assess sinus ostium block [246], and might be use-
ful for screening of sinus disorders and for both post-medical and
post-surgery follow up in patients with bilateral nasal polyposis
[253] and in patients with allergic rhinitis [254]. Therefore, it is
likely that the humming test may also characterize an on–off
response in the presence of advanced ostium disease [255].
Nasal NO has been also investigated in other non-respiratory
diseases such as inherited retinal dystrophies [256].
In conclusion, the use of nNO in diagnosis and monitoring of
respiratory disorders (e.g., allergic rhinitis, sinusitis, nasal polypo-
sis, CF) is potentially of interest, but more research is needed
before we understand how clinically useful these tests are.
Cost effectiveness of using FENO in asthma diagnosis
and management
As described above, FENO measurement can be used for differ-
ent purposes: from diagnosis to management of asthma, including
the evaluation of corticosteroid responsiveness and adherence, and
phenotypization of patients with severe asthma. 
FENO is also promisingly useful in properly prescribing and
monitoring the treatment with novel biological agents together
with other biomarkers of T2 inflammation such as serum IgE and
peripheral blood eosinophils.
Naturally not all the described possible uses have the same
degree of evidences. Guidelines and reviews have graded the evi-
dence for each of the possible uses. While NICE guidelines on
asthma released in 2017 include FENO assessment among the first-
line evaluations for suspect asthma together with lung function
tests in both children and adults [75], a Cochrane review [148]
concluded that strategies based on tailoring asthma medications
dose according only to FENO levels do not have enough evidence
to be translated into clinical practice. Another Cochrane review
stated that while the use of FENO to guide asthma therapy in chil-
dren may be beneficial in a subset of children, it cannot be univer-
sally recommended for all children with asthma [149]. 
Due to the characteristics of the current technology, the meas-
urement of FENO is not expensive and in 2017, in the USA, the pro-
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posed reimbursement by Medicaid was around 20 $ [257], a price
that may lead to a cost-saving policy, both in diagnosing and in the
follow managing asthma. 
A retrospective observational study conducted in USA on
patients hospitalized or treated in emergency department for asth-
ma, demonstrated that direct costs related to asthma exacerbations
can be reduced and almost halved by the use of FENO for monitor-
ing asthmatic patients [258]. 
In Spain it was calculated that adding FENO to standard asthma
care in adults saved 62.53 € per patient/year in adults and
improved QALY, with a potential net yearly saving of €129 million
in the budget of primary care settings [259].
In Italy the situation is patchy; even if FENO measurement has
been recognized at national level as a diagnostic test that can
deserve reimbursement from public health care system, the Italian
State-Region Conference has not approved a specific code and
reimbursement tariff yet. The result is that each region can use dif-
ferent codes (relating to other tests) to classify and price FENO
measurements. Only one region has a specific code for FENO. All
the other ones use existing codes (not specific to FENO) to get the
reimbursement. The tariff also is a haphazard one. It spans from
23.20 euro to 73.00 euro. The rough median is around 24.00 euro.  
Conclusions
FENO is a non-invasive, cheap and easy-to-assess method to assess
airway inflammation, and it has a series of possible advantages
in the management of asthma, both in adults and children
(Figure 2): 
- in the diagnostic process, in which high values of FENO, in
patients with consistent symptoms, confirm the suspect of asth-
ma and the need to do further tests to rule in the diagnosis [43];
on the other hand, low values of FENO are rarely associated with
a final diagnosis of asthma, and therefore they should suggest to
investigate other possible differential diagnosis [43]. These were
the evidence that brought the NICE guidelines [75] to recom-
Figure 2. Fractional exhaled nitric oxide (FENO) usefulness in dif-
ferent aspects of the management of asthma.
Figure 3. Proposed diagnostic algorithm for asthma including FENO in assessment of airway inflammation. 
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mend integrating FENO testing in the diagnostic flowchart for
asthma. We also recommend to use FENO for diagnostic purpose
in combination with lung function assessment and trials with
ICS (Figure 3).
- in the assessment of response to ICS treatment: high FENO
values are associated with an increased probability to achieve
improvement of asthma symptoms after having started (or
increased) ICS treatment [99, 129-131];
- in the evaluation of adherence to ICS treatment: non-adherent
patients tend to have high FENO levels despite the given treat-
ment, and the so-called “FENO suppression test” [130] should be
done in all patients not properly responding to the asthma thera-
py, particularly in difficult-to-treat asthmatics;
- in the phenotypization process of severe asthmatics and as a
biomarker for biologic treatments: FENO is one of the key bio-
marker of type-2 inflammation and high levels are suggestive of
a type-2 inflammatory pathway underlying the asthma patho-
genesis; moreover, patients with high levels of FENO are those
who have the highest probability to respond to anti-IgE and anti-
IL4-receptor-alpha biologic treatments [163-166,169], while it
seems not to be a good response-biomarker for anti-IL5 agents
[167,168].
The use of FENO is suitable and recommendable in both adults
and children, and it should be implemented and encouraged as it
proved to be cost-effective when applied to the management of
patients with (suspect) asthma [257-259]. For these reasons, we
believe that this position paper, like other recently published [260],
can be useful for clinicians taking care about asthmatic patients as
a guide in the interpretation of FENO results.
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